Float Short %

15.95

Margin Of Safety %

Put/Call OI Ratio

0.24

EPS Next Q Diff

1.1

EPS Last/This Y

0.45

EPS This/Next Y

0.36

Price

22.95

Target Price

36.8

Analyst Recom

1.91

Performance Q

14.29

Relative Volume

1.6

Beta

0.77

Ticker: APLS

21 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-04	APLS	18.26	0.21	0.94	54447
2025-07-07	APLS	17.42	0.21	0.24	54606
2025-07-08	APLS	17.89	0.21	0.14	54432
2025-07-09	APLS	19.23	0.21	0.16	54916
2025-07-10	APLS	19.53	0.21	1.28	58801
2025-07-11	APLS	19.45	0.22	0.18	59204
2025-07-14	APLS	19.92	0.22	0.23	59381
2025-07-15	APLS	19.35	0.22	0.36	61477
2025-07-16	APLS	19.75	0.22	0.10	62044
2025-07-17	APLS	20.06	0.22	0.12	63031
2025-07-18	APLS	19.47	0.22	0.52	63860
2025-07-21	APLS	19.28	0.21	0.38	50787
2025-07-22	APLS	19.89	0.21	0.76	51688
2025-07-23	APLS	19.89	0.22	0.07	52152
2025-07-24	APLS	20.12	0.21	0.08	53500
2025-07-25	APLS	19.58	0.21	0.55	54157
2025-07-28	APLS	18.74	0.21	0.11	54463
2025-07-29	APLS	18.95	0.22	0.48	56631
2025-07-30	APLS	19.02	0.22	0.44	57687
2025-07-31	APLS	22.35	0.23	0.26	58614
2025-08-01	APLS	22.95	0.24	1.01	60310
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-04	APLS	18.26	-60.2	23.8	-1.86
2025-07-07	APLS	17.42	-60.2	33.9	-1.86
2025-07-08	APLS	17.89	-60.2	23.5	-1.86
2025-07-09	APLS	19.21	-60.2	16.7	-1.86
2025-07-10	APLS	19.53	-60.2	24.9	-1.86
2025-07-11	APLS	19.44	-60.2	25.6	-1.86
2025-07-14	APLS	19.91	-60.2	23.8	-1.86
2025-07-15	APLS	19.35	-60.2	31.4	-1.86
2025-07-16	APLS	19.74	-60.2	24.5	-1.86
2025-07-17	APLS	20.04	-60.2	25.2	-1.86
2025-07-18	APLS	19.48	-60.2	31.4	-1.86
2025-07-21	APLS	19.27	-60.2	28.8	-1.86
2025-07-22	APLS	19.88	-60.2	22.8	-1.86
2025-07-23	APLS	19.90	-60.2	27.3	-1.86
2025-07-24	APLS	20.09	-60.2	25.9	-1.86
2025-07-25	APLS	19.59	-60.2	30.9	-1.86
2025-07-28	APLS	18.78	-65.6	33.3	-1.28
2025-07-29	APLS	18.95	-65.6	25.8	-1.28
2025-07-30	APLS	19.00	-65.6	27.0	-1.28
2025-07-31	APLS	22.34	-63.2	2.1	-1.15
2025-08-01	APLS	22.95	-63.2	23.4	-1.15
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-04	APLS	-0.46	2.52	24.31
2025-07-07	APLS	-0.46	2.52	24.31
2025-07-08	APLS	-0.46	2.52	24.31
2025-07-09	APLS	-0.45	2.52	24.31
2025-07-10	APLS	-0.45	2.52	24.31
2025-07-11	APLS	-0.45	2.52	25.28
2025-07-14	APLS	-0.45	2.80	25.28
2025-07-15	APLS	-0.34	2.80	25.28
2025-07-16	APLS	-0.96	2.80	25.28
2025-07-17	APLS	-0.96	2.80	25.28
2025-07-18	APLS	-1.06	2.80	25.28
2025-07-21	APLS	-1.06	2.53	25.26
2025-07-22	APLS	-0.98	2.53	25.26
2025-07-23	APLS	-0.98	2.53	25.26
2025-07-24	APLS	-0.82	2.53	25.26
2025-07-25	APLS	-0.81	2.53	15.95
2025-07-28	APLS	-0.81	2.39	15.95
2025-07-29	APLS	-0.81	2.39	15.95
2025-07-30	APLS	-0.81	2.39	15.95
2025-07-31	APLS	-0.78	2.39	15.95
2025-08-01	APLS	-0.78	2.39	15.95
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

-0.74

Avg. EPS Est. Current Quarter

-0.46

Avg. EPS Est. Next Quarter

0.36

Insider Transactions

-0.78

Institutional Transactions

2.39

Beta

0.77

Average Sales Estimate Current Quarter

186

Average Sales Estimate Next Quarter

284

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

75.8

Max Drawdown 5-Year %

-82.5

Target Price

36.8

P/E

Forward P/E

PEG

P/S

3.82

P/B

18.53

P/Free Cash Flow

654.06

EPS

-1.82

Average EPS Est. Cur. Y

-1.15

EPS Next Y. (Est.)

-0.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-30.24

Relative Volume

1.6

Return on Equity vs Sector %

-159.9

Return on Equity vs Industry %

-141.3

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.73

EBIT Estimation

23.4

Apellis Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 705

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

stock quote shares APLS – Apellis Pharmaceuticals, Inc. Stock Price stock today

news today APLS – Apellis Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch APLS – Apellis Pharmaceuticals, Inc. yahoo finance google finance

stock history APLS – Apellis Pharmaceuticals, Inc. invest stock market

stock prices APLS premarket after hours

ticker APLS fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: APLS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y